Pamela J. Cramer - 11 Feb 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Reporting relationship: Chief Human Resources Officer
Issuer ticker: RYTM
Reported as of: 11 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Feb 2026, 17:45:44 UTC
Prior SEC filing: 03 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Vander Stoep, attorney-in-fact for Pamela J. Cramer

Key filing fact

Pamela J. Cramer filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 13 Feb 2026.

Key facts

This page summarizes Pamela J. Cramer's Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 13 Feb 2026, 17:45.

Change

Previous filing in this sequence was filed on 03 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001873517 Primary reporting owner

Cramer Pamela J.

Relationship: Chief Human Resources Officer
Address: C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON
Signature: /s/ Stephen Vander Stoep, attorney-in-fact for Pamela J. Cramer
Signature date: 13 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RYTM transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +11,650
Change %
Price: $0.000000
Shares after: 11,650
Date: 11 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,650
Exercise price
Footnotes: F1, F2

RYTM transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +17,500
Change %
Price: $0.000000
Shares after: 17,500
Date: 11 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,500
Exercise price: $98.47
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Footnote F2

The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.

Footnote F3

The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.